Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Peking University

Status: Unknown

Conditions: Cardiotoxicity; Breast Cancer; Antitumor Drugs; Trastuzumab

Treatments: Drug: Trastuzumab

Study type: Observational

Funder types: Other

Identifiers

NCT04961307

Cardiac safety study

Details and patient eligibility

About

By dynamically observing the changes of echocardiogram and biomarkers in breast cancer patients using trastuzumab, evaluate the effect of trastuzumab on cardiac function; determine the sensitivity of echocardiography and biomarker indicators And specificity, explore effective and specific early warning indicators, and provide technical support for the evaluation of the cardiac safety of anti-tumor drugs.

Full description

Thirty female breast cancer patients using trastuzumab, collected demographic and clinical information of all patients before chemotherapy, performed echocardiography (conventional echocardiography, three-dimensional spot tracking technology), and collected blood samples to detect plasma biology Markers (TnT, BNP, GDF-15, topoisomerase), follow-up echocardiography and biomarkers at 1 month, 3 months and 6 months after chemotherapy.

Enrollment: 30 estimated patients

Sex: Female

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with breast cancer (18-70 years old)
• Patients who are planning to undergo trastuzumab for the first time

Exclusion criteria

• Organic heart disease such as coronary heart disease, heart valve disease, cardiomyopathy
• liver and kidney failure
• severe cerebrovascular disease
• chronic obstructive pulmonary disease
• rheumatic immune system disease
• other tumors

Trial design

30 participants in 1 patient group

Women with breast cancer using trastuzumab

Treatment:

Drug: Trastuzumab